**Main Scientific Publications – Prof. Choi**

1.     Comparison of the data of a next-generationsequencing panel from K-MASTER project with that of orthogonal methods fordetecting targetable genetic alterations. Choi YJ, Choi JY, Kim JW, LimAR, Lee Y, Chang WJ, Lee S, Sung JS, Chung H-J, Lee JW, Kang EJ, Kim JS, Lim T,Kim HS, Kim YJ, Ahn MS, Kim YS, Park JH, Lim S, Cho SS, Cho JH, Sin SW, ParkKH, Kim YH. *Cancer Res Treat.* 2021 May. Online Ahead of print.

2.     E-cigarette and cigarette use among cancersurvivors versus general population: a case-control study in Korea. Paek J, SonS, Choi YJ.*J Cancer Surviv.* 2021 Jun 16. Online Ahead of print.

3.    2020 Korean guidelines for the management of metastatic prostate cancer. KimI-H, Shin SJ, Kang BW, Kang J, Kim D, Kim M, Kim JY, Kim CK, Kim H-J, Maeng CH,Park K, Park I, Bae WK, Sohn BS, Lee M-Y, Lee JL, Lee J, Lim ST, Lim JH, ChangH, Jung JY, Choi YJ, Kim YS, Cho J, Joung JY, Park SH, Lee HJ. Korean JIntern Med. 2021 Feb 10

4.     Antitumor activity and safety of sirolimus forsolid tumors with PIK3CA mutations: A multicenter, open-label, prospectivesingle-arm study (KM 02-01, KCSG UN17-16). Byeon S, Kang MJ, Choi YJ,Kim YJ, Kim M, Yun J, Yi SY, Kim JY, Kim ST, Lee J. Transl Cancer Res2020;9(5):3222-3230. (co-first)

5.     Impact of subsequent chemotherapy on thesurvival of elderly patients with extensive stage small cell lung cancer. KangEJ, Choi YJ, Lee SR, Sung HJ, Kim JS. Korean J Intern Med. 2020Nov;35(6):1468-1476 (co-first)

6.    A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependentosteoclastogenesis and breast cancer growth in the metastatic bonemicroenvironment. Kang J, Choi YJ, Seo BY, Jo U, Park SI, Kim YH, ParkKH. Sci Rep. 2019 Jun 19;9(1):8726.

7.     Association between hand grip strength andimpaired health-related quality of life in Korean cancer survivors: across-sectional study. Paek J, Choi YJ. BMJ Open. 2019 Sep8;9(9):e030938.

8.     Phase II Study of Dovitinib in Patients withCastration-Resistant Prostate Cancer (KCSG-GU11-05). Choi YJ, Kim HS,Park SH, Kim B-S, Kim KH, Lee HJ, Song HS, Shin D-Y, Lee HY, Kim H-G, Lee KH,Lee JL, Park KH. *Cancer Res Treat.*2018 Ict;50(4):1252-1259.

9.     A case report of primary pericardial malignantmesothelioma treated with pemetrexed and cisplatin. Kim JS, Lim SY, Hwang J,Kang EJ, Choi YJ. J Korean Med Sci. 2017;32:1879-1884.

10.The prognostic role of serum C-X-C chemokinereceptor type 4 in patients with metastatic or recurrent colorectal cancer. ChoiYJ, Chang WJ, Shin SW, Park KH, Kim ST, Kim YJ. Oncotargets and Therapy.2016;9:3307-3312.

11.Randomized phase II study ofpaclitaxel/carboplatin intercalated with gefitinib compared topaclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancerin a clinically selected population excluding patients with non-smokingadenocarcinoma or mutated EGFR. Choi YJ, Lee DH, Choi CM, Lee JS, LeeSJ, Ahn J-H, Kim S-W. *BMC Cancer.*2015;15:763.

12.Phase II study of pemetrexed in combinationwith cisplatin in patients with advanced urothelial cancer: the PECULIAR study.Choi YJ, Lee SH, Ahn J-H, Lee K-H, You D, Hong B, Hong JH, Ahn H. *Br J Cancer.* 2015;112:260-265.

13.Pretreatment serum level of 15-kDa granulysinmight have a prognostic value in patients with diffuse large B cell lymphoma.Park Y, Choi YJ, Park SJ, Lee SR, Sung HJ, Park KH, Kim SJ, Choi CW,Jung KY, Kim BS. *Acta Haematol.*2011;126(2):79-86.

14.Epidermal growth factor receptor mutations as aprognostic factor in Korean patients with advanced lung adenocarcinoma who hadnot been treated with received epidermal growth factor receptor tyrosine kinaseinhibitors. Kim ST, Choi YJ, Park KH, Oh SC, Seo JH, Shin SW, Kim JS,Kim YH. *Chemotherapy.*2011;57(2):108-14

15.A prognostic model to identify patients withadvanced pancreas adenocarcinoma who could benefit from second-linechemotherapy. Kim ST, Choi YJ, Park KH, Oh SC, Seo JH, Shin SW, Kim JS,Kim YH. *Clin Oncol (R Coll Radiol).*2012 Mar;24(2):105-11.

16.Mitomycin-C, 5-fluorouracil, and leucovorin asa salvage therapy in patients with metastatic colorectal adenocarcinoma. KangEJ, Choi YJ, Kim JS, Kim ST, Park KH, Choi IK, Oh SC, Seo JH, Shin SW,Kim JS, Kim YH. *Asia Pac J Clin Oncol.*2010Dec;6(4):286-91.

17.Phase II study of dovitinib in patients withmetastatic and/or unresectable gastrointestinal stromal tumours after failureof imatinib and sunintinib. Y-K Kang, C Yoo, B-Y Ryoo, J J Lee, E Tan, I Park,J H Park, Y J Choi, J Jo, J-S Ryu and M-H Ryu. *Br J Cancer*. 2013 Oct 29; 109(9):2309-15.

18.Predictors of mortality attricutable toClostridium difficile infection in patients with underlying malignancy. YoonYK, Kim MJ, Sohn JW, Kim HS, Choi YJ, Kim JS, Kim ST, Park KH, Kim SJ,Kim BS, Shin SW, Kim YH, Park Y. Supportive Care Cancer. 2014;22:2039-2048.

19.Prognostic factors for the selection ofpatients eligible for second-line chemotherapy in advanced biliary tractcancer. Kang EJ, Choi YJ, Kim JS, Park KH, Oh SC, Seo JH, Kim HJ, KangKW, Yu ES, Shin SW, Kim YH, Kim JS. Chemotherapy. 2014;60:91-98.

20.Effectiveness and safety of cabazitaxel plusprednisolone chemotherapy for metastatic castration-resistant prostaticcarcinoma: data on Korean patients obtained by the cabazitaxelcompassionate-use program. Lee J-L, Park SH, Koh S-J, Kim YJ, Choi YJ,Lee J, Lim HY. Cancer Chemother Parmacol. 2014;74:1005-1013.

21.Bladder and liver involvement of visceral larvamigrans may mimic malignancy. Kang EJ, Choi YJ, Kim JS, Lee BH, KangK-W, Kim HJ, Yu ES, Kim YH. Cancer Res Treat. 2014;46(4):419-424.

22.Novel germline mutation of BRCA1 gene in a56-year-old woman with breast cancer, ovarian cancer, and diffuse large B-celllymphoma. Kim HS, Lee SW, Choi YJ, Shin SW, Kim YH, Cho MS, Lee SN, ParkKH. Cancer Res Treat. 2015 Jul;47(3):534-8.

23.A Prognostic index to identify patients withintrahepatic cholangiocarcinoma who could benefit from gemcitabine pluscisplatin. Lee S-Y, Kim HS, Choi YJ, Park KH, Shin SW, Kim YH, Kim ST.Am J Ther. 2015 Jan 29. (Epub)

24.Can serum be used for analyzing the KRASmutation status in patients with advanced colorectal cancer? Kim ST, Shang WJ,Kin L, Sung JS, Choi YJ, Kim YH. Cancer Res Treat. 2015;47(4):796-803.

25.The role of theaddition of ovarian suppression to tamoxifen in young women withhormone-sensitive breast cancer who remain premenopausal or regain menstruationafter chemotherapy (ASTRRA): study protocol for a randomized controlled trialand progress.KimHA, Ahn SH, Nam SJ, Park S, Ro J, Im SA, Jung YS, Yoon JH, Hur MH, Choi YJ,Lee SJ, Jeong J, Cho SH, Kim SY, Lee MH, Kim LS, Moon BI, Kim TH, Park C, KimSJ, Jung SH, Park H, Gwak GH, Kang SH, Kim JG, Kim J, Choi SY, Lim CW, Kim D,Yoo Y, Song YJ, Kang YJ, Jung SS, Shin HJ, Lee KJ, Han SH, Lee ES, Han W, KimHJ, Noh WC. BMC Cancer. 2016;16:319.

26.Prognostic value of axillary nodal ratio afterneoadjuvant chemotherapy of doxorubicin/cyclophosphamide followed by docetaxel:a multicenter retrospective cohort study. Kim SH, Jung KH, Kim T-Y, Im S-A,Choi IS, Chae YS, Baek SK, Kang SY, Park S, Park IH, Lee KS, Choi YJ,Lee S, Sohn JH, Park Y-H, Im Y-H, Ahn J-H, Kim S-B, Kim JH. Cancer Research andTreatment. 2016;48(4):1373-1381.

27.Incidence and predictors of febrile neutropeniaamong early-stage breast cancer patients receiving anthracycline-basedchemotherapy in Korea. Kim HS, Lee SY, Kim JW, Choi YJ, Park IH, Lee KS,Seo JH, Shin SW, Kim YH, Kim JS, Park KH. Oncology. 2016;91(5)274-282.

28.Combination chemotherapy with methotrexate andvinblastine for surgically unresectable, aggressive fibromatosis. Park KH, ChoiYJ, Kim KW, Ro KH, Kang CH, Song SH, Park JH. Jpn J Clin Oncol.2016;46(9):845-9.

29.Overexpression of PD-L2 is associated withshorter relapse-free survival in patients with malignant salivary gland tumors.Chang H, Kim JS, Choi YJ, Cho JG, Woo JS, Kim A, Kim JS, Kang EJ. OncoTargets Ther. 2017;10:2983-2992.

30.Feasibility andEfficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer:Korean Multi-center Phase IV Clinical Study Results. Park YH, Kim TY, Im YH,Lee KS, Park IH, Sohn J, Lee SH, Im SA, Kim JH, Kim SH, Lee SJ, Koh SJ, Lee KH,Choi YJ, Cho EK, Lee S, Kang SY, Seo JH, Kim SB, Jung KH. Cancer ResTreat. 2017;49(2):423-429.

31.Inflammatory markersas prognostic indicators in pancreatic cancer patients who underwentgemcitabine-based palliative chemotherapy. Kim HJ, Lee SY, Kim DS, Kang EJ, KimJS, Choi YJ, Oh SC, Seo JH, Kim JS. *KoreanJ Intern Med*. 2018 Oct 26.

32.Incidence and riskfactors for congestive heart failure in patients with early breast cancer whoreceived anthracycline and/or trastuzumab: a big data analysis of the KoreanHealth Insurance Review and Assessment service database. Choi JY, Cho EY, ChoiYJ, Lee JH, Jung SP, Cho KR, Kim CY, Kim YH, Park KH. Breast Cancer ResTreat. 2018 Aug;171(1):181-188.

33.Detection of somaticvariants and EGFR mutations in cell-free DNA from non-small cell lung cancerpatients by ultra-deep sequencing using the ion ampliseq cancer hotspot paneland droplet digital polymerase chain reaction. Sung JS, Chong HY, Kwon NJ, KimHM, Lee JW, Kim B, Lee SB, Park CW, Choi JY, Chang WJ, Choi YJ, Lee SY,Kang EJ, Park KH, Kim YH. *Oncotarget.*2017 Nov 15;8(63):106901-106912.

34.Quantification ofcirculating cell-free DNA to predict patient survival in non-small-cell lungcancer. Hyun MH, Sung JS, Kang EJ, Choi YJ, Park KH, Shin SW, Lee SY,Kim YH. Oncotarget. 2017 Oct 10;8(55):94417-94430.

35.Early venousthromboembolism at the beginning of palliative chemotherapy is a poorprognostic factor in patients with metastatic pancreatic cancer: aretrospective study. Kim JS, Kang EJ, Kim DS, ChoiYJ, Lee SY, Kim HJ, SeoHY, Kim JS. BMC Cancer. 2018 Dec 17;18(1):1260.

36.A Selective FGFRinhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent osteoclastogenesis andbreast cancer growth in the metastatic bone microenvironment. Kang J, Choi YJ, Seo BY, Jo U, Park SI, Kim YH, Park KH. Sci Rep.2019 Jun 19;9(1):8726.

37.Clinical implicationsof circulating cell-free DNA quantification and metabolic tumor burden inadvanced non-small cell lung cancer. Hyun MH, Lee ES, Eo JS, Kim S, Kang EJ,Sung JS, Choi YJ, Park KH, Shin SW, Lee SY, Kim YH. Lung Cancr. 2019Aug;134:158-166.

38.Completion rate ofphysician orders for life-sustaining treatment for patients with metastatic orrecurrent cancer: a preliminary, cross-sectional study. Kim JW, Choi JY, JangWJ, Choi YJ, Choi YS, Shin SW, Kim YH, Park KH. BMC PalliatCare. 2019 Oct 22;18(1):84.

39.Gemcitabine pluscarboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patientswith advanced urothelial carcinoma: a randomized phase II study (COACH, KCSGGU10-16). Park I, Kim BS, Lim HY, Kim HJ, ChoiYJ, Park KH, Lee KH,Yoon S, Hong B, Hong JH, Ahn H, Lee JL. Eur J Cancer. 2019Oct24.pii:S0959-8049(19)30727-0.

40.Pulmonary function isimplicated in the prognosis of metastatic non-small cell lung cancer but not inextended disease small cell lung cancer. Lee SY, ChoiYJ, Seo JH, Lee SY, KimJS, Kang EJ. J Thorac Dis. 2019 Nov;11(11):4562-4572.

41.Innovativecountermeasures can maintain cancer care continuity during the coronavirusdisease-2019 pandemic in Korea. Lee S, Lim A-R, Kim MJ, Choi YJ, Kim JW,Park KH, Shin SW, Kim YH. Eur J Cancer. 2020 Sep;136:69-75.

42.Pembrolizumab-Induced Myasthenic Crisis withHyperCKemia in a Patient with Thymoma. Shin JH, Choi YJ, Lee J, Baek SH. J Clin Neurol. 2020Jul;16(3):497-498.

43.Clinical Implication of Concordant or DiscordantGenomic Profiling between Primary and Matched Metastatic Tissues in Patientswith Colorectal Cancer. Choi JY, Choi S, Lee M, Park YS, Sung JS, Chang WJ, KimJW, Choi YJ, Kim J, KimD-S, Lee S-H, Seok J, Park KH, Kim SH, Kim YH. Cancer Res Treat. 2020 Jul;52(3):764-778.

44.The Clinical Significance of RAS, PIK3CA, andPTEN Mutations in Non-Small Cell Lung Cancer Using Cell-Free DNA. Chang WJ,Sung JS, Lee SY, Kang EJ, Kwon N-J, Kim HM, Shin SW, Choi JY, Choi YJ, Kim JW, Park KH, Kim YH. Clin Med. 2020 Aug 14;9(8):2642.

45.Clinical Application of Targeted DeepSequencing in Metastatic Colorectal Cancer Patients: Actionable GenomicAlteration in K-MASTER Project. Lee Y, Lee S, Sung JS, Chung H-J, Lim A-R, KimJW, Choi YJ, Park KH, KimYH. Cancer Res Treat. 2021 Jan;53(1):123-130.Treatment Patterns andClinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: ARetrospective Cohort Study. Bang S-M, Kang J-H, Hong MH, Ahn J-S, Oh SY, BaekJH, Choi YJ, Shin SH, Kim Y-J, Gil H-Y, Park H-E, Lee J, Park E-L. ClinAppl Thromb Hemost. Jan-Dec 2021;27:1076029620979575.